Histologic analysis did not sufficiently predict treatment response to certain medications, but methods involving gene expression and transcriptome analysis may be more promising.
Datopotamab deruxtecan led to better progression-free survival and safety compared with standard chemotherapy in patients with metastatic HER-2 negative breast cancer.
Understanding the toxicities associated with antibody-drug conjugates could help oncologists develop strategies to diminish adverse events that arise during treatment with these powerful agents
Combining osimertinib with chemotherapy improved progression-free survival in EGFR-mutated non-small cell lung cancer, new interim data show, but experts have raised concerns about toxicity.